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We  hereby describe the clinical and epidemiological features and, outcomes of nine patients
with Elizabethkingia meningoseptica infections in two hospitals over a 2-year period. All infec-
tions caused by this pathogen were nosocomial, or healthcare associated infections, in
hemodialysis  settings whereas none was correlated with hospital outbreaks.
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Dante  Pazzanese Institute and the Hospital Brigadeiro (SãoWe  hereby describe the clinical and epidemiological fea-
tures  and, outcomes of nine patients with Elizabethkingia
meningoseptica infections in two hospitals over a 2-year period.
All  infections caused by this pathogen were  nosocomial, or
healthcare  associated infections, in hemodialysis settings
whereas  none was  associated with hospital outbreaks.
An  increase of uncommon Gram-negative bacilli has
occurred in the last decade in the nosocomial environment.
A  previous study in Taiwan reported an increased incidence
of  bacteremia caused by E. meningoseptica between 1999 and
2006,  with an incidence rate ranging from 7.5 to 35.6 per
100.000  admissions.1 E. meningoseptica is resistant to multiple
antibiotics and has been previously described as a pathogen of
2neonatal  meningitis and sepsis, as well as a cause of infection
among  immunocompromised patients.3 It causes signiﬁcant
morbidity and mortality rates may  be as high as 50%.2
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E-mail  address: ghpereira1@terra.com.br (G.H. Pereira).
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Este é um artigo Open Access sob a licençaInfections caused by E. meningoseptica have rarely been
identiﬁed, but in the last two years we found that several
patients were diagnosed with nosocomial infections caused
by  this agent. The purpose of this study was  to describe the
clinical  and epidemiological features and the outcomes of
nosocomial  infections caused by E. meningoseptica isolated at
two hospitals involving different specialties.
We conducted a retrospective chart review of patients
with nosocomial infections caused by E. meningoseptica (CDC),4
from August 2010 to April 2012. Patients diagnosed with E.
meningoseptica infections were initially identiﬁed from com-
puter  databases of the hospital infection committees of theBrazil.
Paulo,  Brazil). These two centers are tertiary teaching hospi-
tals  containing a total of 356-beds (73 ICU beds) and 150-beds
(18  ICU beds), respectively. The former provides care for
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linical and surgery cardiac conditions, and the latter for
ransplant  and hematological diseases. The Institutional
thics Committee approved the study and waived the need
or  informed consent.
For  every patient information was  obtained concerning age,
eight,  gender, hospital course of treatment, antibiotic ther-
py  within 30 days of the E. meningoseptica isolation, time
lapsed  from hospital admission to the E. meningoseptica infec-
ion,  length of hospitalization, length of intensive care unit
tay  (LOS ICU), use of invasive procedures such as peripheral or
entral catheters, urinary catheter and mechanical ventilation
ithin  30 days of the E. meningoseptica isolates, surgical pro-
edures,  antibiotic therapy following infection, time elapsed
rom  the E. meningoseptica infection to death and presence
f  infection before, during and after isolating E. meningosep-
ica.
The  isolates had been previously identiﬁed at the micro-
iology laboratory of each hospital using the Vitek® system
bioMérieux, France). Four E. meningoseptica isolates obtained
rom  blood cultures were  sent to the Adolfo Lutz Insti-
ute,  a public health reference laboratory, to conﬁrm the
dentiﬁcation and to perform susceptibility tests. Classical
henotypic methods and API 20 NE System (Biomerieux,
ercy  l’Etoile, France) were  used for bacterial identiﬁcation.
he minimum inhibitory concentrations (MICs) were deter-
ined  by E-test strips (AB Biodisk, Solna, Sweden) for the
ollowing  antimicrobial drugs: quinolones (ciproﬂoxacin and
evoﬂoxacin),  trimethoprim-sulfamethoxazole, minocycline,
nd  vancomycin. These tests were  performed according to the
ecommendations of the Clinical and Laboratory Standards
nstitute.5 Breakpoints for Staphylococcus aureus were  used to
nterpret the MIC  for vancomycin.
Nine  patients were identiﬁed, six from the Dante Pazzanese
nstitute and three from the Brigadeiro Hospital. The clinical
haracteristics of each patient are presented in Table 1.
In  our case series nosocomial infections by E. meningosep-
ica  were  rare in both hospitals. However, in the last two years
his  pathogen has been identiﬁed in the two centers. This ﬁnd-
ng indicates that an increased number of patients have been
nfected  with this bacterium. In addition to previous reports of
nfections  by E. meningoseptica in neonates and immunocom-
romised patients, studies have also described nosocomial
nfections and colonization by E. meningoseptica.6,7 While
ome  authors have reported an increase in bacteremia1,8 due
o  E. meningoseptica, other investigators have described this
athogen  only during outbreaks.3,9–11 The higher incidence of
.  meningoseptica during the study period of two years was not
ssociated  with a hospital outbreak.
At a medical center in Taiwan the majority of patients with
 diagnosis of bacteremia had primary bacteremia, predom-
nantly  acquired in the ICU, but only 6% of the cases were
elated  to catheterization.1 In our study, most of the patients
ith  bloodstream infections had a central line in place. How-
ver,  it is difﬁcult to conclude that a catheter was  the cause
f  primary bacteremia. E. meningoseptica is a bioﬁlm form-
ng  organism, which encourages persistent growth of bacteria
n  catheters. Therapeutic response to bacterial contamina-
ion  of a patient’s catheter is difﬁcult and frequently involves
emoval  of the catheter.12 In an ICU setting, central venous
atheters are often changed if primary bacteremia is detected,3;1 7(5):606–609  607
but  implantable catheters can remain in place.13 The two
patients  in our study with a Port-a-Cath® were successfully
treated with antibiotic therapy.
Pneumonia outbreaks related to mechanical ventilation
caused by E. meningoseptica have been described in acute
care  facilities. Weaver  et al. concluded that caution should
be  used in patients treated with prolonged mechanical ven-
tilation  or transferred to acute care hospitals with this
infection as such patients could serve as an important
source of transmission of this multidrug resistant non-
fermenting Gram-negative bacteria are waterborne pathogens
bacterium.9 Colonization or infection could contaminate
water faucets in intensive care units and cause other envi-
ronmental contamination.10
Chromosomal metallo--lactamase was  shown to be pro-
duced  by E. meningoseptica (GOB-18 and BlaB genes), which
can  hydrolyze most beta-lactam antibiotics and limit their
usefulness  as a therapeutic option.10 E. meningoseptica is nat-
urally  resistant to most -lactams, including carbapenems,14
and, paradoxically, is sensitive to antibiotics that are effec-
tive  against Gram-positive bacteria, such as vancomycin,
quinolones, trimethoprim-sulfamethoxazole, tigecyclin, and
rifampin.15 Our four isolates were  susceptible to quinolones,
minocycline, and trimethoprim-sulfamethoxazole. Based on
the MICs of vancomycin one isolate was considered suscepti-
ble,  three isolates intermediate, and none resistant.
There is no optimal regimen for the treatment of E.
meningoseptica. The relationship between in vitro tests and
clinical  response could be determining in this question.
There is no consensus on standardized susceptibility break-
points  to this pathogen. In some cases, clinical response has
been  satisfactory, even in the presence of high minimum
inhibitory concentrations (MICs).2 Therefore, the relationship
between susceptibility in vitro and the clinical response to
treatment  remains to be established. One study reported
that,  although all isolates were  susceptible to ciproﬂoxacin
in  vitro, three patients did not respond to ciproﬂoxacin ther-
apy  given for 6 or 7 days. After changing the treatment to
vancomycin plus rifampin, all three patients survived.11 The
majority  of our patients were treated with vancomycin or
vancomycin  combined with rifampin or ciproﬂoxacin. Fur-
ther  studies are necessary to determine whether treatment
with  vancomycin alone or in combination with ciproﬂoxacin,
rifampin, or trimethoprim-sulfamethoxazole is more  effective
in  bloodstream infections and pneumonia related to mechan-
ical  ventilation.
A  majority of the patients in the study had a previous infec-
tion  before the diagnosis of E. meningoseptica infection, and half
of them had new infections from different bacteria after treat-
ment.  This fact may  have worsened their clinical conditions
and  may  have been an important factor in the mortality rates
in  the study.
The  risk factors associated with mortality in patients with
E.  meningoseptica, as described in the study, were  hypoalbu-
minemia, increased pulse rate at the onset of infection, the
presence  of a central venous line infection,13,16 shock and
inappropriate use of antibiotics.8Mortality is variable among studies, ranging from 23%1 to
52%.12 In our study, death occurred in 33% of patients, pre-
dominantly in patients with pneumonia.
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Table 1 – Clinical and outcome description of Elizabethkingia meningoseptica infections.
Patient
n◦/Hospital
Age
(years),
gender
Underlying
diseases
Diagnosis  of
infection
diseases
Length  of
hospitalization
(days)
Total length of
ICU/ICU  stay
before  infection
(days)
Time  between
admission and
infection  (days)
Invasive  device
30  days before
infection
1/DPI 1.4; M CHD, PH, malnutrition Pn-MV 87 75/24 36 EI/MV, CVC
2/DPI 0.4; F CHD, DS, congenital
megacolon, malnutrition
BSI  84 10/9 22 EI/MV, CVC
3/DPI 0.4; F CHD, PH, DS Pn-MV 111 41/21 30 EI/MV, CVC
4/DPI 68; M Severe mitral and aortic
valves  insufﬁciency
BSI  66 20/14 60 CVC
5/DPI 64; M Endocarditis  in treatment,
AH  and diabetes
BSI  35 No 11 PVC
6/DPI 81; F CRF, diabetes, AH BSI NA No NA CVC (Shilley)
7/BH 74; M CLL, COP, diabetes,
pneumonia
BSI  81 No 58 Port-a-Cath
8/BH 3; F Liver failure (cause not
determined)
Pn/VM  76 76/45 45 EI/MV, CVC
9/BH 60, F NHL and ASCT BSI 14 No 9 Port-a-Cath
Patient
n◦/Hospital
Surgery or
procedure and
length  time
before infection
(days)
Previous
exposure  to
antibiotics 30
days  before
Susceptibility
tests  MICs
(g/mL)
Therapy, time of
administration
(days)
Associated
infections  before E.
meningoseptica
infection
Outcome  after infection
E.  meningoseptica and
length  between
infection and death
1/DPI Cardiac
catheterization,
23
CFT, VAN, IMP Not performed TEC (16) and TSM
(18)
Pneumonia
Stenotrophomonas
and  chickenpox
Pneumonia  for Proteus
and  Pseudomonas, died
after  51 days
2/DPI Cardiac surgery,
9
CFU,  VAN, IMP Not performed VAN (14) Empiric treatment to
pneumonia  8 days
before  isolated E.
meningoseptica
Transferred  to other
hospital  to correction of
the  megacolon
3/DPI  Cardiac surgery,
10
CFT,  IMP, MER,
VAN,  AMP
Not  performed VAN (21) Pneumonia with
negative  cultures
BSI  for Acinetobacter
iwoﬁi, and pneumonia
4/DPI Cardiac surgery,
57;  pericardial
drainage for 2
times
CFU,  GEN, POL Not performed VAN and RIF (2) BSI for Klebsiella
pneumoniae
carbapenem-
resistant
Urinary  infection for
Proteus  and wound
infection  of surgery for
Providencia  ESBL
positive;  died after 7
days
5/DPI  NA CFT VAN = 4
LEV = 0.094
CIP = 0.025
TSM = 0.19
MIN = 0.25
No treated Presented two
bacteremia and
phlebitis  for
Klebsiella and
Elizabethkingia with
interval  of 2 days
Good  evolution, without
speciﬁc  treatment (only
removal  of peripheral
catheter)
6/DPI  Hemodialysis No VAN = 8
LEV = 0.25
CIP = 0.19
TSM = 0.125
MIN = 0.25
VAN, CIP (21) No Removal of catheter
7/BH Chemotherapy,
17 and
neutropenia, 10
CPE,  LEV, Cl, Mt VAN = 8
LEV = 0.094
CIP = 0.25
TSM = 0.064
MIN = 0.094
VAN (10) Empiric treatment to
pneumonia
Cure  and discharge after
treatment
8/BH  Liver transplant,
69;  pulsotherapy
and tacrolimus
VAN,  MER, LIN,
TSM,  GAN; PTZ,
POL
Not  performed Not performed BSI related catheter
for  S. aureus,
Stenotrophomonas,
Klebsiella and E. coli
Died after 5 days.
b r a z j i n f e c t d i s . 2 0 1 3;1 7(5):606–609  609
Table 1 (Continued )
Patient
n◦/Hospital
Surgery or
procedure and
length  time
before infection
(days)
Previous
exposure  to
antibiotics 30
days  before
Susceptibility
tests  MICs
(g/mL)
Therapy, time of
administration
(days)
Associated
infections  before E.
meningoseptica
infection
Outcome  after infection
E.  meningoseptica and
length  between
infection and death
9/BH Chemotherapy
and neutropenia
No  VAN = 12
LEV = 0.19
CIP = 0.25
TSM = 1.0
MIN = 0.19
VAN (10) None Cure and discharge after
treatment
AMP, ampicillin B; AH, arterial hypertension; ASCT, autologous stem cell transplantation; BSI, bloodstream infection; BH, Brigadeiro Hospital;
CPE, cefepime; CFT, ceftriaxone; CFU, cefuroxime; CIP, ciproﬂoxacin; CVC, central venous catheter; Cl, clarithromycin CHD, congenital heart
diseases; CLL, chronic lymphocytic leukemia; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; DPI, Dante Pazzanese
Institute; DS, Down syndrome; EI, endotracheal intubation; GAN, ganciclovir; GEN, gentamicin; IMP, imipenem; LEV, levoﬂoxacin; LIN, linezolid;
NHL, non-Hodgkin’s lymphoma; MV, mechanical ventilation; Mt, metronidazole; MIN, minocycline; PVC, peripheral venous catheter; PTZ,
ventil
ycin
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1
1
1piperacillin-tazabactam; Pn-VM, pneumonia related to mechanical 
TSM, trimethoprim/sulfamethoxazole; TEC, teicoplanin; VAN, vancom
In conclusion, the prevalence of nosocomial infection by E.
eningoseptica  has increased, predominantly in patients with
evere  underlying diseases, prolonged hospitalization, treat-
ent  with invasive procedures, prior use of broad-spectrum
ntimicrobials and concomitant infections. These factors
ave  impacted survival rates. Further studies are required to
stablish the most effective therapeutic approach.
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